Read about our leadership team, Ribocure board and Science board below.
Dr. Li-ming Gan
Chief Executive Officer
MD, PhD
Dr. Anders Gabrielsen
Chief Medical Officer and Head of Global Clinical Development & Medical Affairs
MD, PhD
Anders Gabrielsen, MD, DMSc, Associate Professor, is a physician scientist with 10+ years of industry experience across the CVRM therapy area. Cardiologist and Internist by training at Karolinska Institutet and Karolinska University Hospitals, with subspecialty in heart failure and core clinical team duties across all aspects of cardiology and internal medicine. Long-standing research experience with translational cardiovascular research focusing on heart failure, pathophysiology, translational vascular biology, atherosclerosis and inflammation with explorative studies including target ID and biomarker exploration studies. Extensive global pharma industry experience working with Bayer, Novartis and AstraZeneca covering multiple CVRM development MoA’s, indications and launches. In the latest role with AstraZeneca served as executive group director for early clinical development with responsibility for cardiovascular and heart failure project clinical activities.
Dr. Sara Svedlund
Head of Ribocure Clinic & Senior Medical Director
MD, PhD
Head of Ribocure Clinic, Ribocure Pharmaceuticals AB.
Sara Svedlund is chief physician and associate professor in non-invasive cardiology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg. Sara has 15 years of clinical experience as physician and is specialized in cardiovascular, exercise and pulmonary physiology. She was licensed physician in 2011 and defended her thesis the same year. Sara became a medical specialist in 2017 and was appointed associate professor in 2019. She was Care Unit Chief Physician at the Clinical Department for Cardiopulmonary Physiology at Sahlgrenska University Hospital during 2016-2022. Research wise, Sara has focused on clinical trials, development and validation of different methodological aspects as well as identification of mechanisms and biomarkers in different cardiovascular patient populations. Further, she has worked extensively with methodological alignment in clinical trials and run an academic echocardiography core lab between 2015-2022. Since March 2022 she is Head of Clinical Operations at Ribocure.
Rebeckha Magnusson
Head of Clinical Operations & Quality Assurance
Maria Liljevald
Head of Global Regulatory Affairs
BSc
Maria Liljevald holds a BSc in molecular biology at the University of Gothenburg and she has 20 years of experience in the pharmaceutical industry. She started her career at AstraZeneca as a lab-based molecular biologist in the transgenic research laboratory in 2004. She moved into preclinical Toxicology 2012. As a Global Toxicology Project Lead, Maria supported drug projects from pre-clinical up to Ph2b, covering various modalities such as oligos, small molecules and Fixed Dose Combination programs in a variety of therapeutic areas. Based on her expertise and experience, she has been on the European Register of Toxicologist (ERT) since 2019. In 2021 Maria took the role as Global Regulatory Lead supporting projects from pre-clinical into Ph2b. She has successfully steered projects through multiple INDs, global Ph2 clinical trial applications, and Health Authority interactions. Recently Maria took on a role as European Regulatory Affairs Lead for a project in the late stage of Ph3 preparing for MAA application. Maria joined Ribocure Pharmaceutical AB in June 2023 as Head of Global Regulatory Affairs.
Dr. Lotta Egnell
Global Head of DMPK & Clinical Pharmacology
MSc, PhD
Lotta (Ann-Charlotte) Egnell has extensive senior leadership experience in Clinical Pharmacology and DMPK with 20 years big pharma industry experience in the CVRM therapy area. Lotta is a pharmacist by training at Uppsala University, Sweden and holds a PhD in translational and computational modeling of atypical enzyme kinetics of drug metabolizing cytochrome P450s from the University of Manchester, UK. Lotta has led the implementation of model based preclinical drug discovery approaches within the CVRM research area at AstraZeneca, and more recently led a team of Clinical Pharmacology Scientists and Clinical Pharmacometricians, supporting a model based clinical development, impacting decision making from Ph1 up to life cycle management. Her project impact spans several different modalities, and from target selection to life cycle management. Lotta also holds a Master in Leadership and Organization, and has extensive line management as well as project leadership experience.
Dr. Johannes Wikström
Head of Bioscience and Global projects
MSc, PhD
Dr. Anna B Granqvist
Senior Project Director
MSc, PhD
Anna B Granqvist has a PhD in Renal medicine/physiology and experience both from working in Academia (15 years) and big pharma company (10 years at AstraZeneca).
She has a broad experience in pre-clinical models (in vitro and in vivo) and was the renal in vivo Team leader for several year supporting the renal strategy and pipeline build at AstraZeneca. She has been Project leader and principal investigator for both pipeline and technical platform projects as well as collaborations with both academic groups and biotech companies.
Dr. Julia Grönros
Project Director External Innovation
MSc, PhD
Julia Grönros holds a MSc in biology and a PhD in physiology at University of Gothenburg from 2008. She did her post doc at Karolinska Institute in a joint venture with AstraZeneca, Gothenburg. Her research interest is within cardiovascular diseases such as atherosclerosis and myocardial infarction, as well as type 2 diabetes. She has worked extensively with developing preclinical animal models for disease and for target validation, with an expertise in ultrasound imaging techniques. Before joining Ribocure, she worked seven years at the Grants and Innovation Office at University of Gothenburg, as responsible research coordinator in the establishment of a successful research Centre within translational and molecular medicine. Julia joined Ribocure in March 2022 as Project Director for External Innovation.
Pontus Boman
Head of Data Science & IT
MSc
Pontus has more than 30 years of experience from Pharmaceutical and Clinical Development. He has worked within the big pharma, small pharma, CRO, technology vendor and public health care sectors in various positions at AstraZeneca, VGR IT, Oncopeptides, Replior, TFS Health Science and Aixial Group. The focus during the last 20 years has been on biometrics, data science and computerized systems catalyzing clinical trials.
Pontus holds a M.Sc. in Chemical Engineering from Chalmers University of Technology, augmented with various university courses in data science, life science and quality management.
Dr. Felix Gnerlich
Head of Chemistry
Dipl. Chem., PhD
Felix is committed to advancing therapeutic oligonucleotides across various therapeutic areas. He has held key roles at renowned organizations in both the biotech and big pharma sectors.
Equipped with a PhD in organic and nucleic acid chemistry, he joined Sanofi’s Nucleic Acid Therapeutics Platform where he was leading a team specializing in synthesis of therapeutic siRNA and targeted delivery for systemic administration.
Transitioning to Rigontec, a clinical-stage biotech company, he spearheaded the chemistry R&D at the startup leveraging his expertise to implement oligonucleotide chemistry capabilities to develop immunostimulatory RNA as cancer drugs. This company was acquired by the US pharma company Merck, Sharp & Dohme in 2017.
Following this success, Felix ventured into AstraZeneca’s Respiratory & Immunology department aiming to establish oligonucleotide therapeutics for respiratory disease. Throughout his tenure, he played a pivotal role in establishing an early-stage pipeline for oligonucleotide drugs in respiratory diseases and helped enhancing the company’s oligonucleotide drug discovery capabilities.
In February 2024, Felix joined Ribocure as Head of Chemistry.
Malin Westberg
Business Planning Lead
Malin Westberg has over 30 years of experience from administrative roles within the pharmaceutical industry. Between 2016 and 2023, Malin was a Senior Administrator and Team Leader within Pharmaceutical Sciences at AstraZeneca. There, she tackled the challenges of recruitment, planning, and shaping of the newly created department, and working closely with the Head of Business Planning and Operations. Malin particularly excels at strategic partnering and business development.
John Taylor
Chief Business Officer
PhD
John is a Business Development leader and has worked across search & evaluation, due diligence & with transactions. He has an established track record of success concluding many in-licensing & out-licensing deals. He has a strong network across global pharma, biotech, and academic environments. John spent significant time at AstraZeneca in Business Development in Gothenburg. Before this a biology department head in AZ Lund, Sweden. John also spent ten years at Pfizer as a Project Leader. John has a Ph.D. for studies on DNA-protein recognition with Prof. Steve Halford (FRS) at Bristol. He then studied DNA mismatch repair with Prof. Paul Modrich (Nobel Laureate 2015) at Duke in the USA.
Anders Waas
Business Development Lead
Anders Waas
Business Development Lead
Dr. Li-ming Gan
Chief Executive Officer & Board member
MD, PhD
Dr. Zicai Liang
Chair of Board
PhD
Dr. Hongyan Zhang
Board member
PhD
Board member , Ribocure Pharmaceuticals AB President, Suzhou Ribo Life Science Co., Ltd.
Dr Hongyan Zhang is one of the co-founders of Suzhou Ribo Life Science Co., Ltd. Since 2007, she has been the Director of Suzhou Ribo Life Science Co., Ltd. responsible for the overall management and operations of the company. Dr. Hongyan Zhang has more than 20 years of experience in academia and biomedicine. She is an expert in small nucleic acid technology and has vast experience in the establishment and operation of biotechnology companies. Under her leadership, Suzhou Ribo Life Science Co., Ltd. has established a professional and efficient R&D department and from scratch, presided more than ten major new drugs to first time in man. Thereby the company realized the first small nucleic acid therapeutics platform in China. Suzhou Ribo Life Science Co., Ltd. has gathered and trained a large number of high-level professional researchers in small nucleic acid technology and pharmaceuticals, formed the largest innovative research and development platform involving the entire technology chain in Asia. Dr. Hongyan Zhang received her Ph.D. in molecular biology from Uppsala University in Sweden and did her postdoctoral research at Yale University School of Medicine in the United States.
Erik Selin
Board member
Business School economist
Erik Selin has over 25 years of experience in investments and corporate leadership across diverse industries. He is the founder and CEO of Fastighets AB Balder and Erik Selin Fastigheter AB. His extensive board commitments include, for example, Norion Bank, Swedish Logistic Property, K-Fast Holding AB, Brinova Fastigheter AB and Hedin Mobility Group AB. Within the medtech industry, Erik also serves as a member of the nomination committee at the Scandinavian orthobiologics company Bonesupport and is chairman of the board at the Swedish medtech company Multi4 Medical.
Professor Lilach Lerman
Advisor renal diseases
MD, PhD
Lilach O. Lerman, MD, PhD, is the Arthur M. and Gladys D. Gray Professor of Medicine and of Physiology in the Mayo Medical School and the Mayo Graduate School. She is the Director of the Renovascular Research Laboratory, Head of the Nephrology Research Unit, and Director of the Regenerative Nephrology Section in the Division of Nephrology & Hypertension at Mayo Clinic. Prof. LO Lerman has been involved in translational nephrology and hypertension research for over 30 years, with a focus on renovascular disease, physiological imaging, the microcirculation, and regenerative medicine.
Professor Stephane Heymans
Advisor cardiomyopathies
MD, PhD
Professor Stefano Romeo
Advisor NASH and lipids
MD, PhD
Professor Jan Borén
Advisor lipid metabolism
MD, PhD
Jan Borén is Professor in Molecular Medicine and physician at the Department of Clinical Chemistry at the Sahlgrenska University Hospital. His main long-term interest is in lipid metabolism and he has focused on understanding the underlying mechanisms leading to and consequences of lipid accumulation in the liver, arterial wall and heart, with the aim of translating this knowledge into effective treatment. His research programme is translational and involves both in vitro and in vivo studies, including pathophysiological studies and mouse models, as well as kinetic studies in carefully phenotyped human volunteers. He combines research with his position as Director of the Institute of Medicine at the University of Gothenburg.
Professor Faiez Zannad
Clinical trialist
MD, PhD
Faiez Zannad is Emeritus
Professor of Therapeutics at Université of Lorraine and Inserm, Nancy, France. He is MD in Cardiology and holds a PhD in Pharmacology. As a clinical trialist he has significantly contributed to building most of the trial-based evidence supporting modern heart failure drug therapy. He developed expertise in biomarker and proteomic science. Has served as Chairman of the French Society of Hypertension and of the Working Group on Pharmacology and Drug Therapy of the European Society of Cardiology (ESC). Dr. Zannad is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, a global think tank dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Asia and the Middle East. Dr. Zannad is recipient of multiple international recognition awards, including as a Highly Cited Researcher award and ESC HFA lifetime achievement award.
CAROLYN S.P. LAM
Advisor cardiology
MBBS, PhD, FRCP, MS, FACC, FAMS, FESC
Dr Lam is Senior Consultant Cardiologist at the National Heart Center Singapore, and Professor at Duke-National University of Singapore. Dr. Lam is recognized globally for her expertise in heart failure with preserved ejection fraction (HFpEF). She is a world-renowned clinical trialist, having contributed to the first approved treatments for HFpEF through her roles on the global steering committees of the PARAGON, DELIVER, FINEARTS-HF, and EMPEROR-Preserved trials. She served on the 2021–2022 European Society of Cardiology Heart Failure Guidelines Task Force and has published over 750 articles in leading journals, including NEJM, JAMA, Lancet, Circulation, and European Heart Journal, earning recognition as a Clarivate Highly Cited Researcher in Clinical Medicine (2021–2024). Dr. Lam serves as Senior Consulting Editor for JACC and is the recipient of the prestigious 2025 National Outstanding Clinician Scientist Award by the Singapore Ministry of Health. In MedTech, she is co-founder of Us2.ai, an award-winning startup applying artificial intelligence to echocardiography to advance the fight against heart disease.
Ribocure will be expanding heavily in Sweden and looking for new talents to join, and academic associations as well as small and large enterprise partners to collaborate with, with the joint goal of developing highly differentiated and innovative oligonucleotide therapeutics to help patients in need.
Sitemap
About Ribocure
Contact us
Ribocure Clinic Privacy-policy
Information om behandling av personuppgifter vid Ribocure Clinic
Ribocure Clinic är en avdelning inom Ribocure Pharmaceuticals AB, org.nr 559366-4377, med adress Vetenskapens gränd 11, 431 53 Mölndal (“Ribocure”, ”vi” eller ”oss”).
Ribocure Pharmaceuticals AB är personuppgiftsansvarig för den behandling av personuppgifter som sker inom ramen för Ribocure Clinics verksamhet och som beskrivs i denna integritetspolicy.
[Vid Ribocure Clinic bedriver vi hälso- och sjukvård och omfattas därmed av patientdatalagen (2008:355) (“PDL”). Vi behandlar personuppgifter i enlighet med Europaparlamentets och rådets förordning (EU) 2016/679 (dataskyddsförordningen, “GDPR”), PDL samt övrig tillämplig dataskyddslagstiftning.]
Denna integritetspolicy beskriver vilka personuppgifter vi samlar in via Ribocure Clinic, för vilka ändamål de behandlas, vilken laglig grund som tillämpas, hur länge uppgifterna lagras, hur journalföring sker samt vilka rättigheter du har i förhållande till behandlingen, inklusive rättigheter enligt PDL.
För ytterligare information om Ribocure och Ribocure Clinic hänvisas till www.ribocure.com respektive www.ribocure.com/ribocure-clinic/.
Vid frågor, synpunkter eller klagomål avseende vår behandling av personuppgifter är du välkommen att kontakta vårt dataskyddsombud via e-post: dpo@ribocure.com.
Ändamål och kategorier av personuppgifter
Ribocure Clinic behandlar personuppgifter för ett antal olika ändamål. Nedan beskrivs de huvudsakliga ändamålen, vilka kategorier av personuppgifter som behandlas, vilken laglig grund som tillämpas samt hur länge uppgifterna lagras.
Rekrytering av forskningspersoner och administration av forskningspersonsdatabasen
När du registrerar dig via vårt anmälningsformulär på https://ribocure.com/forskningsperson, eller vid efterföljande kontakter i samband med rekrytering till kliniska studier, sparas dina uppgifter i vår databas över forskningspersoner. Vi behandlar kontaktuppgifter (namn, telefonnummer, e-postadress), hälsoinformation (t.ex. längd, vikt, läkemedelsanvändning och sjukdomshistoria) samt uppgifter om tidigare studiedeltagande. Laglig grund för behandlingen är ditt samtycke (art. 6.1 a GDPR och art. 9.2 a GDPR).
Vi använder uppgifterna för att identifiera lämpliga forskningspersoner, informera dig om aktuella och kommande studier via e-post, sms eller telefon, samt för att administrera kontakten med dig och hantera bokningar av studiebesök. Dina uppgifter
kan finnas kvar i databasen även om du inte deltar i, eller redan har deltagit i, en studie – detta för att möjliggöra kontakt om framtida studier. Uppgifterna lagras så länge samtycke föreligger och raderas eller anonymiseras vid återkallelse av samtycke.
Om du deltar i en klinisk studie kommer ytterligare personuppgifter att behandlas inom ramen för studiens genomförande. Du erhåller separat information om detta, inklusive uppgift om personuppgiftsansvarig, laglig grund och lagringstid, i samband med att du tillfrågas om att delta.
[Hälso- och sjukvård samt journalföring
I den mån Ribocure Clinics verksamhet utgör hälso- och sjukvård är vi skyldiga att föra patientjournal i enlighet med 3 kap. PDL. Vi behandlar härvid uppgifter som är nödvändiga för en god och säker vård, inbegripet identitetsuppgifter (namn, personnummer), kontaktuppgifter, hälsoinformation, uppgifter om diagnoser, undersökningar, behandlingar och vidtagna åtgärder. Laglig grund för behandlingen är rättslig förpliktelse (art. 6.1 c GDPR) och för känsliga personuppgifter behandling som är nödvändig av skäl som hör samman med hälso- och sjukvård (art. 9.2 h GDPR). Patientjournaler bevaras i minst tio (10) år efter sista anteckningen.]
Utbetalning av arvode för studiedeltagande
Vi behandlar kontaktuppgifter (namn), bankuppgifter och personnummer för att kunna betala ut eventuellt arvode för ditt deltagande i studien. Laglig grund för behandlingen är fullgörande av avtal (art. 6.1 b GDPR) samt rättslig förpliktelse (art. 6.1 c GDPR, bokföringslagen). Uppgifterna lagras i sju (7) år i enlighet med bokföringslagen.
Hantering av förfrågningar och övrig kontakt
Vi behandlar kontaktuppgifter (namn, telefonnummer, e-postadress) samt innehåll i kommunikation med dig för att kunna besvara eventuella frågor eller andra kontakter som du har med oss. Laglig grund för behandlingen är berättigat intresse (art. 6.1 f GDPR), närmare bestämt intresset av att administrera och besvara förfrågningar samt informera om vår verksamhet. Uppgifterna lagras så länge det är nödvändigt för att hantera ärendet, dock som längst tolv (12) månader efter senaste kontakt. Kontakta oss om du önskar mer information om hur vi har vägt dina intressen mot våra.
Statistik och analys av webbplatsanvändning (cookies)
Vi behandlar information om din enhet (till exempel webbläsare och IP-adress), uppgifter om användarbeteende och unika besök för att förstå hur du använder vår webbplats och för att förbättra den. Laglig grund för behandlingen är samtycke (art. 6.1 a GDPR). Lagringstiden framgår av vår separata cookiepolicy.
Delning av personuppgifter
Vi kan komma att dela dina personuppgifter med följande kategorier av mottagare: (i) leverantörer av IT-, telefoni- och systemlösningar som tillhandahåller tjänster för administration av forskningspersonsdatabasen och bokning av studiebesök; (ii) sponsorer eller andra aktörer inom ramen för en klinisk studie, i enlighet med vad som framgår av separat studieinformation; samt (iii) myndigheter, i den utsträckning det krävs enligt lag.
Var behandlas dina personuppgifter?
De personuppgifter vi samlar in behandlas huvudsakligen inom EU/EES. I vissa fall kan uppgifter komma att överföras till och behandlas i länder utanför EU/EES (“tredjeland”). Vid sådana överföringar säkerställer vi att lämpliga skyddsåtgärder vidtas i enlighet med kapitel V GDPR, exempelvis genom användning av EU-kommissionens standardavtalsklausuler (art. 46.2 c GDPR) eller genom att mottagarlandet omfattas av ett beslut om adekvat skyddsnivå (art. 45 GDPR). Du kan begära information om vilka skyddsåtgärder som har vidtagits genom att kontakta oss.
[Hur skyddar vi dina personuppgifter?
Ribocure vidtar lämpliga tekniska och organisatoriska åtgärder för att skydda dina personuppgifter mot obehörig åtkomst, förlust, förstöring eller annan otillåten behandling. Åtkomst till patientuppgifter styrs genom behörighetsstyrning och åtkomstkontroll, vilket innebär att endast den personal som behöver uppgifterna i sitt arbete har tillgång till dem. Åtkomst till patientuppgifter loggas systematiskt och loggkontroller genomförs regelbundet. Motsvarande krav ställs på våra leverantörer. Samtliga medarbetare omfattas av sekretessförpliktelser. Ribocure har utsett ett dataskyddsombud som övervakar efterlevnaden av GDPR.]
Dina rättigheter
Du har rätt till:
Om du vill utöva någon av ovanstående rättigheter är du välkommen att kontakta oss via de kontaktuppgifter som anges nedan. Vi besvarar din begäran utan onödigt dröjsmål och senast inom en (1) månad. Om du vill inge klagomål till Integritetsskyddsmyndigheten (IMY) kontaktar du dem direkt via www.imy.se.
Kontaktuppgifter
Vid frågor om vår behandling av personuppgifter, begäran om att utöva dina rättigheter eller klagomål, vänligen kontakta oss:
Dataskyddsombud: dpo@ribocure.com
Allmän e-post: clinic@ribocure.com
Telefon: 0765-278800
Cookies
Cookies är små textfiler som lagras på din enhet när du besöker vår webbplats. Vi använder funktionella cookies som är nödvändiga för webbplatsens tekniska funktion. Därutöver använder vi, med ditt samtycke, cookies för att samla in statistik om användarbeteende och unika besök i syfte att förbättra webbplatsen. Fullständig information om vilka cookies vi använder och hur du hanterar dina cookieinställningar finns i vår separata cookiepolicy på www.ribocure.com/cookie-policy/.
Länkar till externa webbplatser och sociala medier
Våra webbplatser kan innehålla länkar till externa webbplatser och funktioner kopplade till sociala medier. Dessa tredjeparter är självständigt personuppgiftsansvariga för sin behandling av personuppgifter och Ribocure ansvarar inte för sådan behandling. Vi rekommenderar att du tar del av respektive aktörs integritetspolicy innan du lämnar personuppgifter till dem.
Ändringar i informationen
Ribocure förbehåller sig rätten att uppdatera denna integritetspolicy. Den senaste versionen finns alltid tillgänglig på www.ribocure.com/ribocure-clinic/. Vid väsentliga ändringar som påverkar dig informerar vi om detta på webbplatsen och, i förekommande fall, via e-post eller annan elektronisk kommunikation.
Denna integritetspolicy uppdaterades senast den 21 maj 2026.
Ribocure Pharmaceuticals AB Privacy Policy v1.0